What is Lantern Pharma Scaled Net Operating Assets?
Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.
Lantern Pharma's operating assets for the quarter that ended in Mar. 2024 was $1.38 Mil. Lantern Pharma's operating liabilities for the quarter that ended in Mar. 2024 was $3.78 Mil. Lantern Pharma's Total Assets for the quarter that ended in Dec. 2023 was $43.65 Mil. Therefore, Lantern Pharma's scaled net operating assets (SNOA) for the quarter that ended in Mar. 2024 was -0.05.
Lantern Pharma Scaled Net Operating Assets Historical Data
The historical data trend for Lantern Pharma's Scaled Net Operating Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lantern Pharma Scaled Net Operating Assets Chart
|
Lantern Pharma Annual Data
|
|
Trend |
Dec18 |
Dec19 |
Dec20 |
Dec21 |
Dec22 |
Dec23 |
| Scaled Net Operating Assets |
|
Get a 7-Day Free Trial
|
-0.64 |
0.40 |
0.05 |
0.01 |
- |
|
Lantern Pharma Quarterly Data
|
|
Jun19 |
Sep19 |
Dec19 |
Mar20 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
Dec23 |
Mar24 |
| Scaled Net Operating Assets |
Get a 7-Day Free Trial
|
|
|
|
|
|
|
|
|
|
|
|
|
0.02 |
0.01 |
0.02 |
- |
-0.06 |
Competitive Comparison of Lantern Pharma's Scaled Net Operating Assets
For the Biotechnology subindustry, Lantern Pharma's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lantern Pharma's Scaled Net Operating Assets Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lantern Pharma's Scaled Net Operating Assets distribution charts can be found below:
* The bar in red indicates where Lantern Pharma's Scaled Net Operating Assets falls into.
Lantern Pharma Scaled Net Operating Assets Calculation
Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.
Lantern Pharma's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2023 is calculated as
| Scaled Net Operating Assets (SNOA) | | (A: Dec. 2023 ) |
| = | (Operating Assets (A: Dec. 2023 ) | - | Operating Liabilities (A: Dec. 2023 )) | / | Total Assets (A: Dec. 2022 ) |
| = | (2.345 | - | 2.506) | / | 58.836 |
| = | -0.00 |
where
Lantern Pharma's Scaled Net Operating Assets (SNOA) for the quarter that ended in Mar. 2024 is calculated as
| Scaled Net Operating Assets (SNOA) | | (Q: Mar. 2024 ) |
| = | (Operating Assets (Q: Mar. 2024 ) | - | Operating Liabilities (Q: Mar. 2024 )) | / | Total Assets (Q: Dec. 2023 ) |
| = | (1.376 | - | 3.775) | / | 43.648 |
| = | -0.05 |
where
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lantern Pharma (Lantern Pharma) Business Description
Traded in Other Exchanges
N/A
Address
1920 McKinney Avenue, 7th Floor, Dallas, TX, USA, 75201
Lantern Pharma is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group's growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators.
Executives
| Leslie W. Kreis |
10 percent owner |
1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107 |
| Bios Fund I, Lp |
10 percent owner |
1401 FOCH STREET, SUITE 140, FORT WORTH TX 76107 |
| Bios Fund I Qp, Lp |
10 percent owner |
1401 FOCH STREET, SUITE 140, FORT WORTH TX 76107 |
| Cavu Management, Lp |
10 percent owner |
1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107 |
| Bios Advisors Gp, Llc |
10 percent owner |
1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107 |
| Bios Capital Management, Lp |
10 percent owner |
1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107 |
| Cavu Advisors, Llc |
10 percent owner |
1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107 |
| Bp Directors, Lp |
10 percent owner |
1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107 |
| Bios Fund Ii Nt, Lp |
10 percent owner |
1401 FOCH STREET, SUITE 140, FORT WORTH TX 76107 |
| Bios Fund Ii Qp, Lp |
10 percent owner |
1401 FOCH STREET, SUITE 140, FORT WORTH TX 76107 |
| Bios Fund Ii, Lp |
10 percent owner |
1401 FOCH STREET, SUITE 140, FORT WORTH TX 76107 |
| Bios Equity Partners Ii, Lp |
10 percent owner |
1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107 |
| Bios Equity Partners, Lp |
10 percent owner |
1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107 |
| Fletcher Aaron G.l. |
10 percent owner |
40 GUEST STREET, BOSTON MA 02135 |
| Maria-luisa Maccecchini |
director |
1223 FOXGLOVE LANE, WEST CHESTER PA 19380 |
Lantern Pharma (Lantern Pharma) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
LTRN has been successfully added to your